[MOL] EXE prolongs survival time.... [02389] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] EXE prolongs survival time....



ABSTRACT: Exemestane Is Superior to Megestrol Acetate After Tamoxifen
    Failure in Postmenopausal Women With Advanced Breast Cancer:
    Results of a Phase III Randomized Double-Blind Trial
    [03/30/2000; Journal of Clinical Oncology]

PURPOSE: This phase III, double-blind, randomized, multicenter
study evaluated the efficacy, pharmacodynamics, and safety of
the oral aromatase inactivator exemestane (EXE) versus megestrol
acetate (MA) in postmenopausal women with progressive advanced
breast cancer who experienced failure of tamoxifen. 

CONCLUSION: EXE prolongs survival time, time to tumor progression,
and time to treatment failure compared with MA and offers a
well-tolerated
treatment option for postmenopausal women with progressive advanced
breast cancer who experienced failure of tamoxifen. 

The full article can be found at:

http://www.jco.org/cgi/content/abstract/18/7/1399
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------